US regulators approved GSK Plc’s blood cancer drug, a decision that will allow the company to bring the medicine back to the world’s biggest pharmaceutical market after questions about its effectiveness led to its withdrawal in 2022.
The US Food and Drug Administration cleared GSK’s Blenrep in combination with two other medicines for patients with multiple myeloma, a type of blood cancer, that had come back or hadn’t responded to initial treatment.
The approval comes with a risk mitigation program designed to ensure the medicine is used correctly and to streamline coordination between doctors caring for those who get ...
